688136.SH
科兴制药
SSE · Healthcare · Biotechnology · CN
CNY 23.60
+14.84%Aug 27, 2026, 03:44 UTC
Kexing Pharmaceutical signed a commercialization cooperation agreement with Huayi Taikang Pharmaceutical to jointly promote the commercialization of metoprolol succinate extended-release tablets in the Hong Kong, China market, with Kexing responsible for registration and commercialization.
Source:Aug 21, 2026, 10:05 UTC
Kexing Pharmaceutical announced its first-half 2026 results: revenue of 607 million yuan, net profit of 134 million yuan, up 66.71% year-on-year.
Source:Jun 24, 2026, 03:54 UTC
Kexing Biopharm received the R&D Innovation Award at the CPHI Award ceremony.
Jun 24, 2026, 03:54 UTC
Kexing Biopharm showcased multiple self-developed innovative drug pipelines and over 30 products at the CPHI & PMEC China 2026 exhibition.